Can-Fite completes dosing in Phase III psoriasis interim cohort, eyes Q1 2027 readout
The company also reported a ten-year survival milestone in a Phase II liver cancer patient and new preclinical data tying piclidenoson to kidney benefits in Lowe syndrome.
SEC filing (3)